Loading
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Latest filing published 01 Mar 2024 for Seelos Therapeutics, INC..
Insider track record
Disclosed buys
1
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Michael Joseph Golembiewski: trading record in brief
This profile gathers the share dealings of Michael Joseph Golembiewski across 2 companies, led by Seelos Therapeutics, Inc. and Pernix Therapeutics Holdings, Inc. We count 6 filings; the first trade dates from 8 August 2017 and the latest from 29 February 2024.
Purchases make up the whole of the open-market record (1 purchase, €91k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 5 share grants.
On 1 March 2024 came the latest disclosure, a share grant in Seelos Therapeutics, Inc. The most recent open-market purchase was published on 1 December 2023, 1,058 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Michael Joseph Golembiewski
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
417 shares@ €1.01210.4% of flowCommon StockSEC:0001104659-24-030070:0
83,000 shares@ €1.1004100.0% of flowCommon StockSEC:0001104659-23-122841:0
Canonical exit: 28 Feb 2024 (T+90)
12,500 shares@ €0.56996.1% of flowCommon StockSEC:0001104659-23-097765:0
12,500 shares@ €0.63336.8% of flowCommon StockSEC:0001104659-23-027915:0
12,500 shares@ €0.8058100.0% of flowCommon StockSEC:0001136261-22-000155:0
5 of 5 declarations
